ERBB2 and neoplasm: Frequent actionable mutations comprised PIK3CA mutation (14%, n = 143); BRCA1/2 mutation (6.3%, n = 63); ERBB2 amplification (7.4%, n = 74), and tumor mutation burden‐high (TMB‐H) (5.5%, n = 55), as shown in Table 5.